Roche CERA does not infringe EPO patents
Executive Summary
Final International Trade Commission ruling upholds earlier conclusion that Roche's investigational Continuous Erythropoietin Receptor Activator (CERA) anti-anemia drug "does not infringe any of Amgen's U.S. patents for epoetin," the company says Aug. 31. Amgen filed a complaint April 11 asking ITC to conduct an investigation into whether Roche is illegally importing pegylated recombinant human erythropoietin into the U.S. In July, an ITC administrative law judge determined that Roche's importation is subject to a clinical trial exemption from patent infringement. CERA is currently under development in the U.S. and EU for treatment of renal anemia in chronic kidney disease patients (1"The Pink Sheet" June 26, 2006, p. 17)...
You may also be interested in...
Amgen Expects At-Risk CERA Launch, But Says Swiss Gamble Won’t Pay Off
After failing to block the importation of pegylated erythropoietin, Amgen anticipates Roche will launch its continuous EPO receptor activator Mircera at risk
Roche To Build On Pharma, Diagnostics Expertise For Personalized Medicine
Roche sees its capabilities with both drug and diagnostics development as the key to maintaining a leadership position in targeted oncologics and personalized medicine
How Innovative UTI Diagnostics Can Help Combat Antibiotic Resistance
UTIs are one of the most common reasons for antibiotics to be prescribed, but accurate and timely diagnostic tools are lacking. England’s NICE has identified four innovative IVDs that could be rolled out for NHS patients, but said more research is needed on these products first.